董秘： 您好，谢谢关注。动物医疗是公司定义的高潜力业务之一，公司高度看好动物医疗广阔的市场 空间和未来发展潜力。过去几年公司动物医疗的发展一直受制于产品种类不足，但通过高强度的研发投 入，目前已经基本配备了三大产线所需要补齐的大部分产品，具备了提供一套完整数智化解决方案的能 力，成功带动了海外高端宠物医院突破，今年上半年国际收入占动物医疗业务的比重已经超过了80%。 未来，我们将继续通过在人用产品上成功实现的技术积累和突破的基础上，不断完善动物业务的产品组 合，以此加速海外高端宠物医院的突破。谢谢。 投资者： 董秘好，贵司现在的医疗设备主要用哪家的电源，是否对外有OEM的需求？还请解答，谢 谢。 截至2025年11月6日收盘，迈瑞医疗(300760)报收于206.35元，上涨0.04%，换手率0.5%，成交量6.05万 手，成交额12.51亿元。 董秘最新回复 投资者： 信息披露是专挑好听的是吗，增长区域的数据怎么这么翔实，海外20%增长，利润怎么同比 下滑这么多？拿营销费买收入、低价竞争抢市场，谁不会。创业板指数从2000到3200，贵司股价又要创 新低了，市场都是蠢的吗？请贵司详细定量、定量、定量解释国内 ...

今年上半年，迈瑞医疗国际收入占公司整体收入的比重进一步提升至约50%，其中国际体外诊断产品线 占国际收入的比重已提升至29%，国际动物医疗、微创外科等高潜力业务占国际收入的比重已提升至 12%。 迈瑞医疗要深入推进国际化战略。 "国产医疗器械一哥"迈瑞医疗（300760.SZ）欲赴港上市融资的传闻尘埃落定。 10月14日晚间，迈瑞医疗发布公告称，公司拟在香港联交所主板挂牌上市。 对于这次拟增加上市之地，迈瑞医疗称要深入推进国际化战略，打造国际化资本运作平台。 从去年第三季度以来，因公立医院医疗设备招标低位运行，再加上市场竞争激烈，医疗设备从公开招标 到收入确认的周期延长，迈瑞医疗国内市场收入持续承压，这也进一步拖累公司整体业绩表现。今年上 半年，公司实现营业收入167.43亿元，同比下降18.45%；归属于上市公司股东的净利润50.69亿元，同 比下降32.96%。 截至今年第二季度，迈瑞医疗单季度归属于上市公司股东的净利润已连续四个季度出现同比下滑。与此 同时，公司单季度营业收入也连续三个季度出现同比下降。其中，今年第二季度，公司营业收入同比下 降23.77%，归属于上市公司股东的净利润也同比下降44.55 ...

Core Viewpoint - Company aims to increase international revenue to approximately 50% of total revenue by mid-2025, with a focus on expanding its presence in overseas markets and enhancing local production capabilities [1] Revenue Breakdown - As of now, international revenue accounts for about 50% of the company's overall revenue, with international in vitro diagnostics contributing 29% and international animal healthcare and minimally invasive surgery accounting for 12% of international revenue [1] Future Development Direction - The company plans to maintain a strong focus on international markets, particularly in developing countries, which are expected to grow rapidly [1] - The long-term goal is for international revenue to reach 70% of total revenue, supported by deeper localization efforts and a robust response to changing international conditions [1] Market Position and Strategy - Despite having a market share of only 2-3% in overseas markets, the company believes that the international market potential is significantly larger than the domestic market [1] - The company has established localized production bases in 14 countries, with 11 already in operation, to meet high-end customer demands and comply with local government requirements [1] Stock Performance Insights - Stock price fluctuations are influenced by various factors including company performance, macroeconomic conditions, industry policies, and market sentiment, rather than a single factor [1] - The company expresses confidence in its ability to deliver stable operating performance and healthy profit levels, which are essential for long-term investor returns and market recognition [1]

Summary of the Conference Call for Mindray Medical Company Overview - **Company**: Mindray Medical - **Date**: September 26, 2025 Key Industry Insights - **Market Recovery**: The domestic medical device tendering has shown signs of recovery, but the revenue recognition cycle has lengthened, and the uneven distribution of last year's base has led to limited improvement in the third quarter [2][4] - **Strategic Focus**: Mindray Medical is accelerating import substitution and increasing industry concentration to enhance market share [2][4] Core Strategic Directions - **Digitalization**: Emphasis on AI-enabled devices to enhance customer stickiness and solve clinical problems [2][5] - **Streamlined Operations**: Focus on consumables business growth, including in vitro diagnostic reagents, minimally invasive surgical consumables, and cardiovascular consumables [2][5] - **Internationalization**: Replicating successful experiences and advancing localization to expand sales teams and channels [2][6][8] High-Potential Business Areas - **Minimally Invasive Surgery**: Achieved over 10% market share in the domestic market, with products covering 4K, 3D, and fluorescence technology [2][7] - **Animal Healthcare**: Equipped with necessary products for three major production lines, with international revenue exceeding 80% in the first half of the year [2][7][8] - **Cardiovascular Sector**: Acquisition of Huatai has injected vitality into the business, with the establishment of the electrophysiology division and clinical progress of products like DBA and RFA [2][7][9] Market Performance and Factors - **Third Quarter Performance**: Significant improvement noted, attributed to the gradual easing of multiple factors affecting domestic market growth, including healthcare reform and industry regulation [4] - **Revenue Recognition Delays**: The transition from public tendering to revenue recognition has been significantly prolonged, impacting the timing of revenue realization [4] Additional Insights - **Huatai's Contribution**: The independent operation of Huatai has enhanced the performance of Mindray's cardiovascular business, with successful clinical entry of products and improved operational efficiency [3][9] - **International Market Growth**: Strong performance in international markets, particularly in the high-end pet hospital sector, with a focus on expanding product offerings [8]